Ones To Watch News
Refine Search
Biotechnology
California, USA-based immunology specialist Acelyrin has announced data from the open label Part A of a Phase IIb/III trial in patients with moderate-to-severe Hidradenitis Suppurativa (HS) that demonstrated treatment with its lead candidate izokibep resulted high orders (HiSCR75 and above) of HiSCR response at 12 weeks, including HiSCR100 responses in 33% of participants, claiming these results are better than any seen before. 20 March 2023
Biotechnology
Shares of Canadian biotech Zymeworks dipped 5.5% to $7.90 in after-hours trading on Friday, as the company revealed that its collaboration with Japan’s Daiichi Sankyo has been terminated. 18 March 2023
Biotechnology
US biotech Leap Therapeutics has revealed that Sino-American biotech BeiGene’s option under the exclusive option and license agreement between the companies granting rights DKN-01, Leap's anti-DKK1 monoclonal antibody, has expired in accordance with the terms of the agreement. 17 March 2023
Pharmaceutical
Privately-held Danish dermatology specialist LEO Pharma today presented positive new clinical data from the ECZTRA 6 and ECZTEND trials of Adbry (tralokinumab-ldrm) in adolescent patients aged 12 to 17 years with moderate-to-severe atopic dermatitis (AD), at the American Academy of Dermatology (AAD) 2023 Annual Meeting. 17 March 2023
Pharmaceutical
Esperion Therapeutics’ shares plunged by over 60% to $1.64 on Thursday, after it stated in a company filing with Securities and Exchange Commission (SEC) that Daiichi Sankyo Europe has disputed Esperion’s right to receive milestone payments following a clinical trial. 17 March 2023
Biotechnology
Japanese drugmakers Ono Pharmaceutical and PeptiDream have entered into a new drug discovery collaboration to discover and develop novel macrocyclic constrained peptide drugs against multiple targets of Ono’s interest. 16 March 2023
Biotechnology
Fibrosis-focused Mediar Therapeutics has added $105 million to its coffers. 16 March 2023
Biotechnology
The planned merger of Jounce Therapeutics and UK-based Redx Pharma came under threat yesterday, when Jounce confirmed that it has received an unsolicited offer from Concentra Biosciences to acquire 100% of the company. 16 March 2023
Biotechnology
BioSenic, a Belgian firm specializing in severe inflammatory diseases and cellular repair, has announced that it has re-evaluated the results of its Phase III trial of the enhanced viscosupplement JTA-004 targeting knee osteoarthritis (OA). 16 March 2023
Pharmaceutical
Dermavant Sciences, an immuno-dermatology-focused subsidiary of Switzerland-based Roivant Sciences, has disclosed highly compelling Phase III data from the ADORING 2 trial, the first top-line data from Vtama (tapinarof) in atopic dermatitis (AD) of a two-trial series. 16 March 2023
Biotechnology
Belgian drugmaker UCB has teamed up with US firm Aitia in an early drug discovery collaboration focused on the discovery and validation of new drug targets and candidates for Huntington’s disease. 15 March 2023
Biotechnology
One year after their original agreement, Dutch antibody-drug conjugate (ADC) specialist Synaffix has expanded a deal with MacroGenics. 15 March 2023
article
Shares of Texas, USA-based Bellicum Pharmaceuticals tanked almost 50% to $0.46 this morning after it said it has decided to discontinue its ongoing Phase I/II clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. 15 March 2023
Biotechnology
USA-based tumor drug resistance specialist Deciphera Pharmaceuticals yesterday announced that its Qinlock (ripretinib) has been included in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred regimen for second-line gastrointestinal stromal tumor (GIST) patients intolerant to sunitinib. 15 March 2023
Biotechnology
UK-based company that uses artificial intelligence (AI) in drug discovery Exscientia saw its shares edge up 2.8% to $6.86 in morning trading today, despite announcing that US pharma major Bristol Myers Squibb would not be taking up an option under an agreement with Celgene. 15 March 2023
Biotechnology
The Phase I trial of XMT-2056 has been placed on clinical hold by the US Food and Drug Administration (FDA), said the drug’s developer, US clinical-stage biotech Mersana Therapeutics, whose shares fell over 2% to $4.6 in pre-market trading today 13 March 2023
Pharmaceutical
Exenatide, a GLP-1 agonist sold under the brand names Byetta and Bydureon by AstraZeneca (LSE: AZN) as a type 2 diabetes drug, could be useful in another indication, a trial has found. 13 March 2023
Pharmaceutical
Two American firms have agreed terms for the joint commercialization of the novel attention deficit/hyperactivity disorder (ADHD) candidate CTx-1301 (dexmethylphenidate). 13 March 2023
Biotechnology
Provention Bio’s shares skyrocketed 262% to $24.27 in pre-market trading today, on the news that French pharma major Sanofi had made a takeover bid for the US biotech. 13 March 2023
Pharmaceutical
Shares of US drug developer Intercept Pharmaceuticals closed almost 14% lower at $16.12 on Friday, after it revealed that the US regulator will hold an advisory committee meeting to review its re-submitted approval request for its investigational non-alcoholic steatohepatitis (NASH) treatment obeticholic acid (OCA). 13 March 2023
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze